Table 4

Subgroup results of PFS and heterogeneity test

VariablesAnalysis numberHR (95% CI)Heterogeneity test
Q P value I2 (%)
Total PFS92.567 (1.562 to 4.219)18.100.02155.6
Region
 Asian10.421 (0.084 to 2.114)0.00
 Caucasian82.883 (1.830 to 4.544)12.990.07246.1
Sample size
 >10052.559 (1.372 to 4.774)9.260.05556.8
 ≤10042.536 (0.943 to 6.818)8.750.03365.7
Follow-up (month)
 ≥6062.153 (0.984 to 4.710)13.080.02361.8
 <6033.158 (1.774 to 5.623)3.560.16943.8
Stage
 All NMIBC34.673 (1.938 to 11.264)3.290.19339.2
 Others62.044 (1.213 to 15.040)9.580.08847.8
Cut-off
 15%12.800 (1.447 to 5.418)0.00
 Others82.515 (1.382 to 4.576)17.920.01260.9
Publication year
 ≥201251.685 (0.883 to 3.215)8.040.09050.2
 <201244.176 (2.209 to 7.884)5.000.17240.0
Patient age (year)
 ≥7022.519 (1.377 to 4.606)0.600.4380.0
 <7072.654 (1.381 to 5.100)17.400.00865.5
Multivariate/univariate
 Multivariate62.101 (1.070 to 1.121)13.830.03163.8
 Univariate32.803 (1.652 to 7.856)3.380.00140.8
  • NMIBC, non-muscle invasive bladder cancer; PFS, progression-free survival.